Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) at the European Society of Human Genetics Annual Meeting 2015
Highlights in vitro Pre-Clinical Data for Novel Gene-Therapy Drug Candidate for Treatment of RDEB—a Rare, Congenital, Devastating Skin DiseaseEXTON, Pa. and GERMANTOWN, Md., May 28, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, together announced today that a poster will be presented highlighting in vitro pre-clinical data for FCX-007, a gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa (...
Intrexon to Present at the Jefferies 2015 Global Healthcare Conference
GERMANTOWN, Md., May 26, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon's Health Sector, will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3rd, at 1:30 p.m. Eastern Time at the Grand Hyatt in New York City. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  The Company's integrated technology suite provides its partners across diverse markets with industrial-scal...
Intrexon Announces First Quarter 2015 Financial Results
- Net income of $27.1 million or $0.26 per basic share - - Adjusted EBITDA of $(11.3 million) or $(0.11) per basic share - - Declares Special Stock Dividend of ZIOPHARM Shares - GERMANTOWN, Md., May 11, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its first quarter results for 2015.  Business Highlights and Recent Developments: Entered into an exclusive collaboration and license agreement with the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, to develop and commercialize chimeric antigen receptor T-cell (CAR-T) cancer therapies. Utilizing Intrexon's cell engineering techniques and RheoSwitch® platfor...
Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015
GERMANTOWN, Md., May 4, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release first quarter 2015 financial results after the market closes on May 11, 2015.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International) and asking to join the "Intrexon Conference Call."  Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biolog...
1